LifeMD Inc

LifeMD Inc(LFMD)の株式分析

$3.140

-0.116 (-3.68%)終値時点

Loading chart…
High
3.300
Open
3.260
VWAP
3.19
Vol
466.44K
Mkt Cap
279.29M
Low
3.140
Amount
1.49M
EV/EBITDA, TTM
-3.86

LifeMD, Inc. is a patient-centric, direct-to-patient healthcare company. The Company is engaged in providing patients access to virtual medical care and pharmacy services. Its telehealth platform helps patients access licensed providers for diagnoses, virtual care, and prescription medications, often delivered on a recurring basis and sells over the counter (OTC) products. Its products are available on a subscription or membership basis, where a patient can subscribe to receive regular shipments of prescribed medications or products. The Company's men's brand, RexMD, offers access to virtual medical treatment for a variety of men's health needs, including erectile dysfunction, premature ejaculation and hair loss. Its vertically integrated care model combines technology, affiliated clinical services, pharmacy infrastructure, and artificial intelligence (AI)-enabled operational systems to deliver longitudinal care.

lifemd.com

AI analysis of LifeMD Inc (LFMD)

hold

LifeMD Inc is currently not a strong buy due to its low current price of $3.14 and a concerning RSI of 33.801, indicating potential oversold conditions. The company has shown a significant 49.11% decline over the past year, and while analysts have a price target range between $5 and $9, the recent earnings miss and lowered guidance suggest caution. The main risk is the negative net income of -7.86 million in Q2 2026, which highlights ongoing profitability issues.

バリュエーション指標

The current forward P/E ratio for LifeMD Inc (LFMD) is 12.85, compared to its 5-year average forward P/E of -16.24.

Forward P/E

Fair
5Y Average P/E
-16.24
Current P/E
12.85
割高
43.08
割安
-75.56

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
5.78
Current EV/EBITDA
-3.86
割高
18.37
割安
-6.81

Forward P/S

Fair
5Y Average P/S
0.96
Current P/S
0.64
割高
1.41
割安
0.52

Alphio AI Price Scenarios for LFMD

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%LFMD

$14.58

シナリオ価格

B

Base

Base · 50%LFMD

$13.42

シナリオ価格

B

Bear

Bear · 25%LFMD

$9.37

シナリオ価格

イベントタイムライン

2026-08-05 (ET)

18:30:00

LifeMD Sees Q3 Adjusted EBITDA Loss of $1M to Gain of $2M

18:30:00

LifeMD Cuts FY26 Revenue Outlook to $6B Loss

18:00:00

LifeMD Reports Q2 Revenue of $47.3M

2026-06-22 (ET)

09:30:00

LifeMD Partners with Antares Pharma for Xyosted Self-Pay Program

2026-06-01 (ET)

09:00:00

LifeMD Appoints Umesh Sripad as Chief Technology Officer

ニュース

LFMD FAQ — answered by Alphio AI

LifeMD, Inc. is a patient-centric, direct-to-patient healthcare company. The Company is engaged in providing patients access to virtual medical care and pharmacy services. Its telehealth platform helps patients access licensed providers for diagnoses, virtual care, and prescription medications, often delivered on a recurring basis and sells over the counter (OTC) products. Its products are available on a subscription or membership basis, where a patient can subscribe to receive regular shipments of prescribed medications or products. The Company's men's brand, RexMD, offers access to virtual medical treatment for a variety of men's health needs, including erectile dysfunction, premature ejaculation and hair loss. Its vertically integrated care model combines technology, affiliated clinical services, pharmacy infrastructure, and artificial intelligence (AI)-enabled operational systems to deliver longitudinal care. It operates in the Healthcare sector (SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE industry).

LifeMD Inc is currently not a strong buy due to its low current price of $3.14 and a concerning RSI of 33.801, indicating potential oversold conditions. The company has shown a significant 49.11% decline over the past year, and while analysts have a price target range between $5 and $9, the recent earnings miss and lowered guidance suggest caution. The main risk is the negative net income of -7.86 million in Q2 2026, which highlights ongoing profitability issues.

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

無料で始める